Development of Rational Drug Combinations with Investigational Targeted Agents

Por Clark, Adam, Ellis, Matthew, Erlichman, Charles, Lutzker, Stuart, Zwiebel, James
Publicado em 2010

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer and pancreatic cancer

Por Mansfield, Aaron S., Fields, Alan P., Jatoi, Aminah, Qi, Yingwei, Adjei, Alex A., Erlichman, Charles, Molina, Julian R
Publicado em 2013

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Por Mattison, Ryan, Jumonville, Alcee, Flynn, Patrick James, Moreno-Aspitia, Alvaro, Erlichman, Charles, Laplant, Betsy, Juckett, Mark B.
Publicado no Leuk Lymphoma (2014)

Phase II Trial of Gemcitabine and Tanespimycin (17AAG) in Metastatic Pancreatic Cancer: A Mayo Clinic Phase II Consortium Study

Por Pedersen, Katrina S., Kim, George P., Foster, Nathan R., Wang-Gillam, Andrea, Erlichman, Charles, McWilliams, Robert R.
Publicado no Invest New Drugs (2015)

Cisplatin Abrogates the Geldanamycin-induced Heat Shock Response

Por McCollum, Andrea K., Lukasiewicz, Kara B., TenEyck, Cynthia J., Lingle, Wilma L., Toft, David O., Erlichman, Charles
Publicado em 2008

Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons

Por Gálvez-Peralta, Marina, Flatten, Karen S., Loegering, David A., Peterson, Kevin L., Schneider, Paula A., Erlichman, Charles, Kaufmann, Scott H.
Publicado em 2014

Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells

Por Rao, Ravi D, Mladek, Ann C, Lamont, Jeffrey D, Goble, Jennie M, Erlichman, Charles, James, C David, Sarkaria, Jann N
Publicado em 2005

A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tissue Sarcomas: A Study of the Mayo Phase 2 Consortium (P2C)

Por Okuno, Scott, Bailey, Howard, Mahoney, Michelle R., Adkins, Douglas, Maples, William, Fitch, Tom, Ettinger, David, Erlichman, Charles, Sarkaria, Jann N.
Publicado em 2011

Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells

Por Huehls, Amelia M., Wagner, Jill M., Huntoon, Catherine J., Geng, Liyi, Erlichman, Charles, Patel, Anand G., Kaufmann, Scott H., Karnitz, Larry M.
Publicado em 2011

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

Por Schenk, Erin, Wahner Hendrickson, Andrea E., Northfelt, Donald, Toft, David O., Ames, Matthew M., Menefee, Michael, Satele, Daniel, Qin, Rui, Erlichman, Charles
Publicado em 2013

Phase 2 Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer

Por Philip, Philip A., Mahoney, Michelle R., Holen, Kyle D., Northfelt, Donald W., Pitot, Henry C., Picus, Joel, Flynn, Patrick J., Erlichman, Charles
Publicado em 2011

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies

Por Hubbard, Joleen M., Kim, George, Borad, Mitesh J., Johnson, Elizabeth, Qin, Rui, Lensing, Janet, Puttabasavaiah, Suneetha, Wright, John, Erlichman, Charles, Grothey, Axel
Publicado no Invest New Drugs (2015)

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Por Hubbard, Joleen, Erlichman, Charles, Toft, David O., Qin, Rui, Stensgard, Bridget A., Felten, Sara, Eyck, Cynthia Ten, Batzel, Gretchen, Ivy, S. Percy, Haluska, Paul
Publicado em 2010

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

Por Cashen, Amanda, Juckett, Mark, Jumonville, Alcee, Litzow, Mark, Flynn, P. J., Eckardt, John, LaPlant, Betsy, Laumann, Kristina, Erlichman, Charles, DiPersio, John
Publicado em 2011

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

Por Attia, Steven, Kolesar, Jill, Mahoney, Michelle R., Pitot, Henry C., Laheru, Daniel, Heun, James, Huang, Wei, Eickhoff, Jens, Erlichman, Charles, Holen, Kyle D.
Publicado no Invest New Drugs (2008)

P-glycoprotein-mediated resistance to HSP90-directed therapy is eclipsed by the heat shock response

Por McCollum, Andrea K., TenEyck, Cynthia J., Stensgard, Bridget, Morlan, Bruce W., Ballman, Karla V., Jenkins, Robert B., Toft, David O., Erlichman, Charles
Publicado em 2008

A STUDY OF PACLITAXEL, CARBOPLATIN, AND BORTEZOMIB IN THE TREATMENT OF METASTATIC MALIGNANT MELANOMA: A PHASE II CONSORTIUM STUDY

Por Croghan, Gary A., Suman, Vera J., Maples, William J., Albertini, Mark, Linette, Gerald, Flaherty, Lawrence, Eckardt, John, Ma, Cynthia, Markovic, Svetomir N., Erlichman, Charles
Publicado em 2010

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Por Kumar, Shaji K., LaPlant, Betsy, Chng, Wee Joo, Zonder, Jeffrey, Callander, Natalie, Fonseca, Rafael, Fruth, Briant, Roy, Vivek, Erlichman, Charles, Stewart, A. Keith
Publicado no Blood (2015)

SAFETY AND ACTIVITY OF TEMSIROLIMUS AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA PREVIOUSLY TREATED WITH TYROSINE KINASE INHIBITORS: A PHASE 2 CONSORTIUM STUDY

Por Merchan, Jaime R., Qin, Rui, Pitot, Henry, Picus, Joel, Liu, Glenn, Fitch, Tom, Maples, William J., Flynn, Patrick J., Fruth, Briant F., Erlichman, Charles
Publicado no Cancer Chemother Pharmacol (2015)

HER receptor signaling confers resistance to the insulin-like growth factor 1 receptor inhibitor, BMS-536924

Por Haluska, Paul, Carboni, Joan M., Eyck, Cynthia Ten, Attar, Ricardo M., Hou, Xiaonan, Yu, Chunrong, Sagar, Malvika, Wong, Tai W., Gottardis, Marco M., Erlichman, Charles
Publicado em 2008